Biggest investment in Russia’s Cancer, Diabetes, HIV, and Stroke vaccines in 2024 : Pharma stocks

Recently, Russian President Vladimir Putin has said that Russia is now creating pharmaceutical companies like others in the world, where there are up to 80% chances of getting a cancer vaccine for the first time in the world. Russia’s other SOTIO, NII Oncology Institute, and BIOCAD are such companies that will be able to make many types of vaccines in the future such as Cancer, Diabetes, Heart Transplants, HIV, and other vaccines for Strokes. If Russia can now make a vaccine for a disease like Cancer, then in the future Russia can also find a solution to the world’s most common diseases and make a Therapy or Vaccine. And now Russia has led the world in terms of the pharmaceutical industry and now it is believed that Russia can become the world’s largest vaccine exporter, medical science, and other top country in pharmaceutical stocks.

Top countries investing in Russia’s Cancer, Diabetes, HIV, and Stroke vaccines in 2024

In the future, the stocks of Russia’s top pharmaceutical companies like BAYER, SANOFI, TEVA, and SERVIER may also touch the sky. if Russia’s Cancer vaccine gives successful results, then Russia’s other interest in diabetes, HIV, and Stroke will also be visible in European, Asian, African, and American populations in the future. Due to this US, British, Indian, Chinese and European Pharma companies will also suffer a huge loss and those companies will also deal with Russia on Ideas, Technology, and Science. And now it is also said that if Russia makes a Cancer Vaccine then in the future Russia will give pharma vaccine technology, medical strategy, and science to other countries that they can trust. like Iran, China, North Korea, the Middle East, the African Union, and South American. Because recently Iran and China have given possible help to Russia from all sides, which even India and Israel did not do. Russia could also retail and trade cancer, diabetes, HIV, and stroke vaccines in Europe to prop up its US pharma sector but development would be done only with select countries. Due to this other European companies will also increase their relations with Russia and sell cheap medicines.